» Articles » PMID: 8486791

Protamine and Protamine-insulins Exacerbate the Vascular Response to Injury

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1993 May 1
PMID 8486791
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Endothelial cells and smooth muscle cells produce heparinlike compounds that are growth inhibitory for vascular smooth muscle cells, and it has been suggested that these compounds play a regulatory role that is perturbed with vascular injury. Indeed, exogenous heparin preparations effectively suppress smooth muscle cell proliferation following injury imposed on vascular endothelium. We now report that protamine, an agent that binds heparin and negates its anticoagulant properties, has potent stimulatory effects on vascular smooth muscle cell proliferation. The administration of protamine, alone or as part of commonly used insulin preparations, stimulated the proliferation of cultured smooth muscle cells, exacerbated vascular smooth muscle cell proliferative lesions in laboratory rats, and interfered with the growth-inhibitory effects of heparin in culture and in vivo. These results confirm the importance of endogenous heparinlike compounds in arterial homeostasis and may require reconsideration of protamine use following vascular reparative procedures and in diabetics.

Citing Articles

Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo.

Lovich M, Edelman E Proc Natl Acad Sci U S A. 1999; 96(20):11111-6.

PMID: 10500138 PMC: 17995. DOI: 10.1073/pnas.96.20.11111.


CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury.

Hancock W, Adams D, Wyner L, Sayegh M, Karnovsky M Am J Pathol. 1994; 145(5):1008-14.

PMID: 7977633 PMC: 1887438.


Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model.

Simons M, Edelman E, Rosenberg R J Clin Invest. 1994; 93(6):2351-6.

PMID: 7911126 PMC: 294440. DOI: 10.1172/JCI117240.


Tissue engineered perivascular endothelial cell implants regulate vascular injury.

Nathan A, Nugent M, Edelman E Proc Natl Acad Sci U S A. 1995; 92(18):8130-4.

PMID: 7667257 PMC: 41109. DOI: 10.1073/pnas.92.18.8130.

References
1.
Yayon A, Klagsbrun M, Esko J, Leder P, Ornitz D . Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991; 64(4):841-8. DOI: 10.1016/0092-8674(91)90512-w. View

2.
Kurtz A, Gray R, Markanday S, Nabarro J . Circulating IgG antibody to protamine in patients treated with protamine-insulins. Diabetologia. 1983; 25(4):322-4. DOI: 10.1007/BF00253194. View

3.
Edelman E, Adams D, Karnovsky M . Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci U S A. 1990; 87(10):3773-7. PMC: 53985. DOI: 10.1073/pnas.87.10.3773. View

4.
Andrade S, Fan T, Lewis G . Quantitative in-vivo studies on angiogenesis in a rat sponge model. Br J Exp Pathol. 1987; 68(6):755-66. PMC: 2013085. View

5.
Guyton J, Rosenberg R, Clowes A, Karnovsky M . Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res. 1980; 46(5):625-34. DOI: 10.1161/01.res.46.5.625. View